The treatment of clinically localized prostate cancer is controversial. Options include radical prostatectomy, external-beam radiation therapy (EBRT), brachytherapy, cryotherapy, and watchful waiting.
Methods
The author reviews EBRT as treatment for clinically localized prostate cancer, with particular emphasis on the technological advances that have allowed dose escalation and fewer therapy-related side effects.
Results
Technological advances in the last two decades have significantly improved the delivery of EBRT to the prostate. This has resulted in an overall increase in the total dose that can be safely delivered to the prostate, which has led to modest improvements in biochemical outcome. An alternative approach of combining androgen suppression therapy and EBRT has also been successful in improving clinical outcomes. However, establishing the optimal therapy for prostate cancer remains controversial.
Conclusions
Recent progress has led to improvements in clinical outcomes in patients treated with EBRT for prostate cancer. It is hoped that the next decades will bring continued advances in the development of biologicals that will further improve current clinical outcomes.
References
1.
JemalA., SiegelE., WardE.Cancer statistics, 2006. CA Cancer J Clin.2006; 56: 103–130.
2.
BucciM.K., BevanA., RoachMIII. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin.2005; 55: 117–134.
3.
Intensity Modulated Radiation Therapy Collaborative Working Group.Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys.2001; 51: 880–914.
4.
Ten HakenR.K., FormanJ.D., HeimburgerD.K.Treatment planning issues related to prostate movement in response to differential filling of the rectum and bladder. Int J Radiat Oncol Biol Phys.1991; 20: 1317–1324.
5.
PickettB., RoachMIII, VerheyL.The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys.1995; 32: 211–218.
6.
RoachMIII, Faillace-AkazawaP., MalfattiC.Prostate volumes and organ movement defined by serial computerized tomographic scans during three-dimensional conformal radiotherapy. Radiat Oncol Investig.1997; 5: 187–194.
7.
LangenK.M., JonesD.T.Organ motion and its management. Int J Radiat Oncol Biol Phys.2001; 50: 265–278.
8.
TrichterF., EnnisR.D.Prostate localization using transabdominal ultrasound imaging. Int J Radiat Oncol Biol Phys.2003; 56: 1225–1233.
9.
LangenK.M., PouliotJ., AnezinosC.Evaluation of ultrasoundbased prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys.2003; 57: 635–644.
10.
HuangE., DongL., ChandraA.Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys.2002; 53: 261–268.
11.
PouliotJ., AubinM., LangenK.M.(Non)-migration of radiopaque markers used for on-line localization of the prostate with an electronic portal imaging device. Int J Radiat Oncol Biol Phys.2003; 56: 862–866.
12.
AubinS., BeaulieuL., PouliotS.Robustness and precision of an automatic marker detection algorithm for online prostate daily targeting using a standard V-EPID. Med Phys.2003; 30: 1825–1832.
13.
WongJ.R., GrimmL., UematsuM.Image-guided radiotherapy for prostate cancer by CT-linear accelerator combination: prostate movements and dosimetric considerations. Int J Radiat Oncol Biol Phys.2005; 61: 561–569.
14.
PouliotJ., Bani-HashemiA., ChenJ.Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys.2005; 61: 552–560.
15.
LetourneauD., MartinezA.A., LockmanD.Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients. Int J Radiat Oncol Biol Phys.2005; 62: 1239–1246.
OldhamM., LetourneauD., WattL.Cone-beam-CT guided radiation therapy: a model for on-line application. Radiother Oncol.2005; 75: 271–278.
18.
SchellhammerP.F., el-MahdiA.M., HigginsE.M.Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy. J Urol.1987; 137: 897–901.
19.
ScardinoP.T., WheelerT.M.Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr.1988: 95–103.
20.
ScardinoP.T.The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol.1983; 1: 243–252.
21.
MillerE.B., LadagaL.E., el-MahdiA.M.Reevaluation of prostate biopsy after definitive radiation therapy. Urology.1993; 41: 311–316.
22.
KubanD.A., el-MahdiA.M., SchellhammerP.The significance of postirradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys.1992; 24: 409–414.
23.
CrookJ., RobertsonS., CollinG.Clinical relevance of transrectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys.1993; 27: 31–37.
24.
BabaianR.J., KojimaM., SaitohM.Detection of residual prostate cancer after external radiotherapy: role of prostate specific antigen and transrectal ultrasonography. Cancer.1995; 75: 2153–2158.
25.
PollackA., ZagarsG.K., SmithL.G.Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol.2000; 18: 3904–3911.
26.
PollackA., ZagarsG.K., StarkschallG.Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys.2002; 53: 1097–1105.
27.
ZietmanA.L., DeSilvioM.L., SlaterJ.D.Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA.2005; 294: 1233–1239.
28.
SathyaJ.R., DavisI.R., JulianJ.A.Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol.2005; 23: 1192–1199.
29.
RagdeH., GradoG.L., NadirB.Modern prostate brachytherapy. CA Cancer J Clin.2000; 50: 380–393.
30.
AshD.Advances in radiotherapy for prostate cancer. Br J Radiol.2005; 78(spec no 2): S112–S116.
31.
HolmH.H., JuulN., PedersenJ.F.Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol.1983; 130: 283–286.
32.
D'AmicoA.V., WhittingtonR., MalkowiczS.B.Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA.1998; 280: 969–974.
33.
KupelianP.A., PottersL., KhuntiaD.Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys.2004; 58: 25–33.
34.
BrachmanD.G., ThomasT., HilbeJ.Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys.2000; 48: 111–117.
35.
PeschelR.E., ColbergJ.W.Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol.2003; 4: 233–241.
36.
MerrickG.S., ButlerW.M., WallnerK.E.Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys.2005; 61: 32–43.
37.
DattoliM., WallnerK., TrueL.Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer.2003; 97: 979–983.
38.
SylvesterJ.E., BlaskoJ.C., GrimmP.D.Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys.2003; 57: 944–952.
39.
PickettB., KurhanewiczJ., PouliotJ.Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys.2006; 65: 65–72. Epub 2006 Mar 6.
PilepichM.V., WinterK., LawtonC.A.Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys.2005; 61: 1285–1290.
42.
PilepichM.V., WinterK., JohnM.J.Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys.2001; 50: 1243–1252.
43.
LawtonC.A., WinterK., GrignonD.Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic nodepositive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol.2005; 23: 800–807.
44.
BollaM., GonzalezD., WardeP.Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med.1997; 337: 295–300.
45.
BollaM., ColletteL., BlankL.Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet.2002; 360: 103–106.
46.
HanksG.E., PajakT.F., PorterA.Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol.2003; 21: 3972–3978. Erratum in: J Clin Oncol. 2004; 22: 386.
47.
D'AmicoA.V., ManolaJ., LoffredoM.6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA.2004; 292: 821–827.
48.
LaverdiereJ., GomezJ.L., CusanL.Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys.1997; 37: 247–252.
49.
LaverdiereJ., NabidA., De BedoyaL.D.The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol.2004; 171: 1137–1140.
50.
CrookJ., LudgateC., MaloneS.Report of a multicenter Canadian phase III randomized trial of 3 months vs 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys.2004; 60: 15–23.
51.
RoachMIII, DeSilvioM., LawtonC.Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol.2003; 21: 1904–1911.
